Biliary tract cancer: our experience with gemcitabine treatment
Biliary tract cancer: our experience with gemcitabine treatment
复制标题
DOI：
10.1097/00001813-200010000-00006
复制
发表时间：
2000-10-01
影响因子：
2.3
通讯作者：
Di Leo, R
中科院分区：
文献类型：
--
作者：
Verderame, F;Mandina, P;Di Leo, R
胆道癌是一种罕见的肿瘤，预后很差，因为大多数患者在诊断时表现为浸润性癌症，使他们无法手术。化疗是一种姑息治疗，但单一药物或联合方案的有效率为14-18%，有效时间为8.5个月。我们报告了吉西他滨治疗晚期胆道癌患者的单中心经验。本文报告了4例化疗后晚期胆道癌患者用吉西他滨1g/m，q1，8，15天治疗。经过3个周期的治疗，我们观察到1例部分缓解，3例稳定(按WHO标准)，所有患者的表现状态都有所改善，疼痛完全缓解。观察到进展的中位时间为10.7个月。虽然这种经验仅限于少数患者，但它表明吉西他滨似乎值得在这种肿瘤病理中进行临床研究，并使该药物成为研究胆道恶性肿瘤患者的特别有趣的药物。[(C)2000 Lippincott Williams&Wilkins]。
Biliary tract cancers are uncommon tumors, with a poor prognosis because most patients present an invasive cancer at diagnosis that makes them inoperable. Chemotherapy is a palliative treatment, but single drugs or combination schedules have demonstrated a response rate of 14-18%, with a duration of response of 8.5 months. We report a single center experience with gemcitabine in the treatment of patients with advanced biliary tract cancers. We report on four cases of chemonaive patients with advanced biliary tract cancers treated with gemcitabine 1 g/m q days 1, 8 and 15. After three cycles of treatment we observed one partial response and three stable disease (according to WHO criteria), with an increase in performance status and a complete relief of pain in all patients. The median time to progression observed was 10.7 months. Although this experience is limited to a small number of patients, it shows that gemcitabine appears to be worthy of clinical research in this neoplastic pathology and makes the drug a particularly interesting agent for investigation in patients with biliary tract malignancies. [(C) 2000 Lippincott Williams & Wilkins].